Samsung Biologics Co Ltd (207940) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Samsung Biologics Co Ltd (207940) has a cash flow conversion efficiency ratio of 0.051x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩619.30 Billion ≈ $419.69 Million USD) by net assets (₩12.18 Trillion ≈ $8.25 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 207940 net asset quality score to measure how much of total assets are equity-financed.
Samsung Biologics Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Samsung Biologics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Samsung Biologics Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Samsung Biologics Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Samsung Biologics Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ferrovial SE
NASDAQ:FER
|
0.024x |
|
Sun Life Financial Inc.
TO:SLF
|
0.047x |
|
China Citic Bank Corp Ltd Class A
SHG:601998
|
0.217x |
|
East Money Information Co Ltd
SHE:300059
|
-0.037x |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-A
|
0.151x |
|
WuXi AppTec Co Ltd
SHG:603259
|
0.070x |
|
Diageo plc
MX:DEON
|
0.065x |
|
Shanghai Pudong Development Bank Co Ltd
SHG:600000
|
0.109x |
Annual Cash Flow Conversion Efficiency for Samsung Biologics Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Samsung Biologics Co Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Samsung Biologics Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩10.90 Trillion ≈ $7.39 Billion |
₩1.66 Trillion ≈ $1.12 Billion |
0.152x | -10.23% |
| 2023-12-31 | ₩9.83 Trillion ≈ $6.66 Billion |
₩1.67 Trillion ≈ $1.13 Billion |
0.169x | +59.79% |
| 2022-12-31 | ₩8.98 Trillion ≈ $6.09 Billion |
₩953.05 Billion ≈ $645.87 Million |
0.106x | +16.46% |
| 2021-12-31 | ₩4.99 Trillion ≈ $3.38 Billion |
₩454.60 Billion ≈ $308.07 Million |
0.091x | +107.27% |
| 2020-12-31 | ₩4.60 Trillion ≈ $3.12 Billion |
₩202.09 Billion ≈ $136.95 Million |
0.044x | +1784.58% |
| 2019-12-31 | ₩4.35 Trillion ≈ $2.95 Billion |
₩10.15 Billion ≈ $6.88 Million |
0.002x | +129.35% |
| 2018-12-31 | ₩4.16 Trillion ≈ $2.82 Billion |
₩-33.02 Billion ≈ $-22.38 Million |
-0.008x | -121.09% |
| 2017-12-31 | ₩3.98 Trillion ≈ $2.69 Billion |
₩149.82 Billion ≈ $101.53 Million |
0.038x | +345.46% |
| 2016-12-31 | ₩4.08 Trillion ≈ $2.77 Billion |
₩-62.66 Billion ≈ $-42.46 Million |
-0.015x | +83.96% |
| 2015-12-31 | ₩2.77 Trillion ≈ $1.88 Billion |
₩-265.51 Billion ≈ $-179.93 Million |
-0.096x | +44.27% |
| 2014-12-31 | ₩630.73 Billion ≈ $427.44 Million |
₩-108.30 Billion ≈ $-73.39 Million |
-0.172x | -- |
About Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line de… Read more